Abstract

Introduction: Viral load testing is essential to manage HIV disease, especially in infants and children. Early infant diagnosis (EID) is performed using nucleic-acid testing in children under 18 months. Resource-limited health systems face severe challenges to scale-up both viral load and EID to unprecedented levels. Streamlining laboratory systems would be beneficial to improve access to quality testing and to increase efficiency of antiretroviral treatment programmes. We evaluated the performance of viral load testing to serve as an EID assay in children younger than 18 months.

Methods: This study was an observational, prospective study, including children between one and 18 months of age who were born to HIV-positive mothers in 134 health facilities in Maputo City and Maputo Province, Mozambique. Dried blood spot specimens from heel or toe pricks were collected between January and April 2018, processed using SPEX buffer for both assays, and tested for routine EID and viral load testing using the Roche CAP/CTM HIV-1 Qualitative v2 and Roche CAP/CTM HIV-1 Quantitative v2 assays respectively. The sensitivity, specificity and positive and negative predictive values were estimated using the EID results as the reference standard.

Results: A total of 1021 infants were included in the study, of which 47% were female. Over 95% of mothers and children were on antiretroviral treatment or received antiretroviral prophylaxis respectively. The sensitivity and specificity of using the viral load assay to detect infection were 100% (95% CI: 96.2 to 100%) and 99.9% (95% CI: 99.4 to 100%). The positive and negative predictive values were 99.0% (95% CI: 94.3 to 100%) and 100% (95% CI: 99.6 to 100%). The McNemar’s test was 1.000 and Cohen’s kappa was 0.994.

Conclusions: The comparable performance suggests that viral load assays can be used as an infant diagnostic assay. Infants with either low levels of viraemia or high cycle threshold values should be repeat tested to ensure the result is truly positive prior to treatment initiation, regardless of assay used. Viral load assays could replace traditional EID testing, substantially streamlining molecular laboratory services for children and lowering costs, with the additional advantage of providing baseline viral load results for antiretroviral treatment management.

Keywords: diagnostics; paediatrics; testing; virology; LMIC; Africa; viral load monitoring
approximately 50% of HIV-positive infants may die before two years of life if left untreated [4]. Unfortunately, however, globally only approximately 50% of HIV-positive infants were initiated on antiretroviral treatment (ART) in 2017 [1]. Efficient and effective testing systems are critical to ensure infants are identified early and quickly linked to life-saving ART.

Challenges remain in the EID testing network, both globally and within Mozambique. Reagent stock outs, small infant testing volumes, requirements for sample batching and high commodity prices persist [5]. Additionally, the logistics of managing two different yet similar assays for EID and viral load testing may fragment supply chain management and procurement. Many of these challenges, alone or in combination, can lead to testing delays or stoppages. Furthermore, test suppliers have noted manufacturing challenges and delays due to the small EID market size and sporadic procurement. Due to the high morbidity and mortality rates of HIV-infected infants, delays in diagnosis can be detrimental. HIV molecular diagnostic laboratories in Mozambique typically conduct both EID and viral load testing in the same laboratory and using the same technologies. However, performing different tests in the same laboratory and on the same equipment can cause complications; therefore, separation of sample processing and testing as distinct workflow and processing stations are often implemented.

In 2010, the World Health Organization (WHO) recommended that several assays could be used to diagnose infants and children under 18 months of age, including HIV RNA testing on plasma or dried blood spot testing (DBS) [6]. Consolidating and simplifying testing using viral load assays as an infant diagnostic may reap significant benefits, particularly as countries could access often lower viral load prices, remove the necessity to batch samples, unify procurement and consolidate volumes to ensure consistent reagent supply. We, therefore, conducted a diagnostic accuracy study to determine the performance of a viral load assay to accurately diagnose HIV infection in HIV-exposed infants under 18 months of age in Mozambique.

2 | METHODS

2.1 | Study design and participants

This was an observational, prospective study that included infants between one and 18 months of age born to HIV-1-positive mothers in need of a routine HIV EID test. Infants excluded from the study were those less than one month old and older than 18 months of age or with low quality specimen, according to the rejection criteria used for HIV EID routine testing in Mozambique. Samples were collected from 134 health facilities that attend to infants born to HIV-positive mothers in Maputo City and Maputo Province between January and April 2018.

Dried blood spot specimens were collected and referred to the National Institute of Health Reference laboratory in Maputo for EID routine testing and viral load testing. Demographic and clinical data for study participants were collected using a routine EID form, including gender, age and exposure to maternal treatment and infant prophylaxis. Because patient identifiers were not collected, remnant spots from routine clinical samples were used, and only standard clinical test results were provided to caregivers and clinicians, individual consent was waived and approval by the Institutional Review Boards that reviewed the protocol.

2.2 | Test methods

Dried blood spot specimens (Whatman 903, GE Healthcare Biosciences, Pittsburgh, PA, USA) were drawn from the heel or toe pricks of eligible infants and transported within three weeks to the reference laboratory for early infant diagnosis HIV-1 PCR testing using the Roche CAP/CTM 96 HIV-1 Qualitative Test v2 (Roche Molecular Diagnostics, Branchburg, NJ, USA). Low quality specimens were excluded, including those without full dried blood spots and when two or more cards were in the same ziplock bag without glassine paper between the cards. This test detects extracellular and intracellular HIV-1 RNA and proviral DNA in whole blood specimens. The Roche software automatically corrects for the haematocrit value in dried blood spot specimens.

Infants were determined positive when the Roche CAP/CTM qualitative EID assay reported a detectable result with a cycle threshold less than 31. National policy states that laboratories should implement an indeterminate range that includes results with a cycle threshold (Ct) value of 31 or greater using the Roche CAP/CTM EID assay; infants with an initial EID cycle threshold value in this range received a second EID test, if possible, either on the same or a new sample before a definitive test result is determined. The EID definitive result was determined based on the test result of the second (repeat) Roche CAP/CTM EID test. If the repeat EID test result was target not detected, the infant was determined to be HIV negative. If the repeat EID test result was a detectable result, the infant was determined to be HIV positive. In this study, the viral load results were not used to determine positivity nor were they returned to the healthcare facility or caregiver.

After the EID test result, HIV-1 viral load testing was performed using the Roche CAP/CTM 96 HIV-1 Quantitative Test v2 (Roche Molecular Diagnostics, Branchburg, NJ, USA) using remnant specimens. The Sample Pre-Extraction (SPEX) solution was used for DBS elution for both qualitative and quantitative testing. The routine EID test results were returned to the healthcare facility and caregiver per national guidelines. Viral load test results were not provided to health care facilities or caregivers and were used for study purposes only.

The reference laboratory routinely participated in and passed external quality assessment programmes for both EID and viral load (provided by the Center for Disease Control and Prevention, Atlanta, USA) prior to and during the study period.

2.3 | Analysis

The sensitivity and specificity of quantitative testing (HIV viral load) as well as the positive and negative predictive values were estimated using the qualitative assay (EID) as the reference. Cohen’s kappa and McNemar’s test were also performed. Only valid results (detectable or undetectable) were used for these calculations; invalid results were excluded. Additionally, we conducted a sub-analysis to determine the diagnostic accuracy of the viral load and EID assays if the indeterminate range is not implemented and the EID definitive result is based solely on the initial EID test result. We compared demographic data between HIV-positive and HIV-negative groups using the Chi-square test. Data were analysed using SAS/STAT software version 9.4 (SAS Institute Inc, Cary, NC, USA).
2.4 | Protocol approval

This study was approved by the Mozambique National Health Bioethics Committee, Advarra Institutional Review Board in the USA, and the Ethics Review Committee from the World Health Organization, Geneva, Switzerland.

3 | RESULTS

3.1 | Patient population

A total of 1021 infants were included in the study (Figure 1), of which 46.9% were female (Table 1). The median age of all infants was 33 days (IQR: 31 to 61 days), while 68.9% were less than 60 days old. The proportion of infants who tested positive for HIV with the EID assay was 9.3% (n = 95). Nearly all mothers were on antiretroviral treatment (95.8%) and 95.7% of infants were given antiretroviral prophylaxis at the time of testing. The majority (87.7%) of infants were exclusively breastfed.

3.2 | Data analysis

Of the 95 infants determined to be HIV positive, the median viral load on the quantitative assay was 944,421 copies/mL (IQR: 51,715 to 2,405,127), while the median cycle threshold value on the qualitative assay was 24.4 (IQR: 22.5 to 27.9). The median cycle threshold value on the quantitative assay was 24.5 (IQR: 23.0 to 28.3). The majority (90 of 95) quantitative results were within four cycles of the qualitative results (−1 to + 3 cycles) (Table S1). Just over half (55%, n = 53) of the HIV-positive infants had an EID cycle threshold value less than 25, 30% (n = 29) had a cycle threshold value between 25 and 30, 14% (n = 13) had a cycle threshold value between 30 and 35, and 1% (n = 1) had a cycle threshold value greater than 35.

The HIV-positive infants were significantly older than the HIV negative (64.5 vs. 33 days, p < 0.001), while 71.3% of HIV-negative infants were less than 60 days old only 45.3% of HIV-positive infants were less than 60 days old (p < 0.001). Of the HIV-positive infants, 89.5% of mothers were on treatment compared to 96.5% of HIV-negative infants (p = 0.033), while 93.7% of HIV-positive infants were on prophylaxis compared to 95.9% of HIV-negative infants (p = 0.312). Ninety-five percent of HIV-positive infants were exposed to antiretroviral drugs through either maternal treatment or infant prophylaxis, while 99% of HIV-negative infants were similarly exposed.

The sensitivity and specificity of the viral load assay to correctly diagnose HIV infection compared to the EID assay was 100.0% (95% CI: 96.2 to 100%) and 99.9% (95% CI: 99.4 to 100%) respectively (Table 2). The positive and negative predictive values were 99.0% (95% CI: 94.3 to 100%) and 100.0% (95% CI: 99.6 to 100%). Cohen’s kappa was 0.994 (95% CI: 0.989 to 0.999) and McNemar’s test was 1.000 (p = 0.3173). One infant was falsely positive by the viral load assay. The infant was 84 days old at the time of testing, receiving infant prophylaxis, and exposed to maternal antiretroviral treatment. The viral load result was < 400 copies/mL and Ct value of 35.3 (Patient #5, Table 3). The infant had an initial positive EID test results with a Ct value of 31.6. The subsequent test on the same sample was negative and, therefore, the definitive result was HIV negative.

Mozambique implements an indeterminate range that includes results with a cycle threshold on the Roche CAP/CTM EID assay of 31 or greater. Infants with an initial EID cycle threshold result equal to or above 31 receive a second EID test before a diagnosis is determined. We, therefore, sought to determine the performance of the EID and viral

| Included in the study | n = 1021 |
|-----------------------|----------|
| Tested with EID       | n = 1021 |
| EID results positive  | n = 95   |
| median Ct: 24.4 (IQR: 22.5 – 27.9) |
| VL results positive   | n = 95   |
| median Ct: 24.5 (IQR: 23.0 – 28.3) |
| EID results negative  | n = 926  |
| VL results positive   | n = 1    |
| VL results negative   | n = 925  |

Figure 1. Flow diagram of study participants.
load assays if the indeterminate range was not applied. Without considering the indeterminate range, the sensitivity of the viral load assay was 96.0% (95% CI: 90 to 98.9%), while the specificity was 99.9% (95% CI: 99.4 to 100%) (Table 3). In this sub-analysis, there were five potentially false-positive viral load test results. The initial EID cycle threshold results of each were 40.9, 34.3, 34.2, 33.5 and 31.6 (Table 4). However, when the indeterminate range was implemented and follow-up testing conducted, four of the five initially EID positives tested negative (target not detected) on either the same or a new sample and were determined to be HIV negative. Without an indeterminate range, the false-positive rate of the EID assay was 4.0% (95% CI: 1.1 to 10.0).

Table 1. Study participant characteristics

| EID test result | Negative n (%) | Positive n (%) | Total n (%) | Chi-square p-value | t-test p-value |
|----------------|----------------|----------------|-------------|--------------------|---------------|
| Sex            |                |                |             |                    |               |
| Female         | 428 (46.2%)    | 51 (53.7%)     | 479 (46.9%) | 0.276              |               |
| Male           | 417 (45.0%)    | 39 (41.1%)     | 456 (44.7%) |                    |               |
| Not available  | 81 (8.7%)      | 5 (5.3%)       | 86 (8.4%)   |                    |               |
| Age            |                |                |             |                    |               |
| 30 to 60 days  | 660 (71.3%)    | 43 (45.3%)     | 703 (68.9%) |                    |               |
| 61 to 90 days  | 62 (6.7%)      | 11 (11.6%)     | 73 (7.1%)   |                    |               |
| 91 to 180 days | 51 (5.5%)      | 16 (16.8%)     | 67 (6.6%)   | <0.001             |               |
| 181 to 270 days| 51 (5.5%)      | 10 (10.5%)     | 61 (6.0%)   |                    |               |
| ≥271 days      | 28 (3.0%)      | 8 (8.4%)       | 36 (3.5%)   |                    |               |
| Not available  | 74 (8.0%)      | 7 (7.4%)       | 81 (7.9%)   |                    |               |
| Median age (IQR) | 33 (31 to 60) | 64.5 (43 to 162) | 33 (31 to 61) | <0.001 |               |
| Infant prophylaxis |            |                |             |                    |               |
| None           | 12 (1.3%)      | 4 (4.2%)       | 16 (1.6%)   | 0.055              | 0.312         |
| AZT/NVP        | 888 (95.9%)    | 89 (93.7%)     | 977 (95.7%) |                    |               |
| Not available  | 26 (2.8%)      | 2 (2.1%)       | 28 (2.7%)   |                    |               |
| Mothers prophylaxis |          |                |             |                    |               |
| None           | 7 (0.8%)       | 5 (5.3%)       | 12 (1.2%)   | 0.003              | 0.033         |
| ART/NVP/AZT + 3TC | 893 (96.4%)  | 85 (89.5%)     | 978 (95.8%) |                    |               |
| Not available  | 26 (2.8%)      | 5 (5.3%)       | 31 (3.0%)   |                    |               |
| Breastfeeding  |                |                |             |                    |               |
| None           | 49 (5.3%)      | 8 (8.4%)       | 57 (5.6%)   | 0.132              |               |
| Exclusive      | 820 (88.6%)    | 75 (78.9%)     | 895 (87.7%) |                    |               |
| Mixed          | 9 (1.0%)       | 2 (2.1%)       | 11 (1.1%)   |                    |               |
| Not available  | 48 (5.2%)      | 10 (10.5%)     | 58 (5.7%)   |                    |               |
| Total          | 926 (90.7%)    | 95 (9.3%)      | 1021        |                    |               |

Table 2. Results of viral load quantitative testing compared with early infant diagnosis qualitative testing

| Viral load result | Detected | Not detected | Sensitivity (95% CI) | Specificity (95% CI) | PPV (95% CI) | NPV (95% CI) |
|------------------|----------|--------------|----------------------|----------------------|--------------|--------------|
| EID result       | Positive | 95           | 0                    | 100.0%               | 99.9%        | 100.0%       |
|                  | Negative | 1            | 925                  | (96.2 to 100.0%)     | (99.4 to 100.0%) | (94.3 to 100%) |

Cohen's kappa (95% CI): 0.994 (0.989 to 0.999). McNemar's test (p): 1.000 (p = 0.3173).

4 | DISCUSSION

Previous studies have suggested that viral load testing can be used as an infant diagnostic [7–9]; however, most studies were conducted in developed settings and prior to 2005 when maternal treatment and infant prophylaxis were poorly implemented and not yet widespread in sub-Saharan Africa. Exposure to antiretroviral drugs can significantly reduce mother to child transmission [10–14], but also reduce the amount of virus at diagnosis of HIV-infected infants [15]. The present study is the first to find similarly high sensitivity (100%) and specificity (99.9%) of the viral load assay when being used as a diagnostic for early infant diagnosis in a high.
HIV burden setting with high exposure rates to antiretroviral drugs. In 2010, the World Health Organization recommended that early infant diagnosis can be performed targeting a variety of nucleic acids, including DNA and RNA [6]; however, it is not clear that the guidelines recommend the use of either qualitative or quantitative assays. The data presented here provide a proof of principle that both assay types can be used to accurately diagnose HIV-exposed infants.

The results of this study are highly generalizable. Sample sizes within the highest cycle threshold or lower viral load values were included with nearly 30% of infants having an initial EID cycle threshold result above 30. No infants less than one month of age were included, so the generalizability to birth testing may be limited. While HIV-positive infants tested at birth generally have lower levels of virus [15], we still observed high sensitivity amongst infants with high Ct values or low levels of virus, regardless as to age. Furthermore, sampling was done consecutively until the sample size was reached representing a typical population attending primary health care facilities in Mozambique. Finally, maternal treatment and infant prophylaxis rates were very high in the included population; greater than 95% of mothers and infants were on treatment or receiving prophylaxis respectively.

Previous studies have reported discordant or false-positive values using molecular technologies, either qualitative or quantitative assays [16–18]. While there is a correlation between the cycle threshold value and the level of virus in a sample, the various circulating viral subtypes, assay techniques, and use of older technologies can lead to discordant PCR results. Unfortunately, no assay is or will likely be perfect. However, it is understood that the viral load in infants can predict the Ct values of qualitative assays [19]. Due to the changing dynamics of mother-to-child transmission (MTCT) – increased proportions of women in prevention of mother-to-child transmission (PMTCT) programs, incident infections and later MTCT, lower levels of virus at infant diagnosis due to exposure to maternal treatment and infant prophylaxis, and introduction and widespread use of dolutegravir in pregnant and breastfeeding women – definitive HIV diagnosis of infants will become more challenging, yet previous studies and our results suggest that this may not be due to technological or performance barriers.

Table 3. Results of viral load quantitative testing compared with early infant diagnosis qualitative testing, without utilizing an indeterminate range

| EID result | Detected | Not detected | Sensitivity (95% CI) | Specificity (95% CI) | PPV (95% CI) | NPV (95% CI) |
|------------|----------|--------------|---------------------|----------------------|-------------|--------------|
| Positive   | 95       | 4            | 96.0% (90.0 to 98.9%) | 99.9% (99.4 to 100.0%) | 99.0% (94.3 to 100%) | 99.6% (98.9 to 99.9%) |
| Negative   | 1        | 925          |                     |                      |             |              |

Cohen’s kappa (95% CI): 0.972 (0.961 to 0.982). McNemar’s test (p): 1.800 (p = 0.1797).

Table 4. Initial and follow-up early infant diagnosis and viral load results of all samples with initial early infant diagnosis qualitative cycle threshold values above 31

| First sample | Second sample | EID definitive result | Viral load result (copies/mL) | Viral load Ct |
|--------------|---------------|----------------------|------------------------------|--------------|
| Patient 1    |               | Ct 1                 | Ct 2                         |              |
| 1            |               | 40.9                 | Not detected                 |              |
| 2            |               | 34.3                 | Not detected                 |              |
| 3            |               | 33.5                 | Not detected                 |              |
| 4            |               | 34.2                 | Not tested                   |              |
| 5            |               | 31.6                 | Not detected                 |              |
| 6            |               | 31.6                 | Not tested                   |              |
| 7            |               | 31.6                 | 32.2                         |              |
| 8            |               | 32.8                 | Not tested                   |              |
| 9            |               | 31.3                 | 31.1                         |              |
| 10           |               | 31.5                 | 31.2                         |              |
| 11           |               | 31.2                 | 31.9                         |              |
| 12           |               | 32.4                 | Not tested                   |              |
| 13           |               | 33.2                 | Not tested                   |              |
| 14           |               | 31.5                 | Not tested                   |              |

Grey shading, false positive case; NA, not available; N/A, not applicable or additional testing unnecessary as definite result determined; Not detected, target not detected; Not testing, additional sample unavailable.

Vubil A et al. Journal of the International AIDS Society 2020, 23:e25422
http://onlinelibrary.wiley.com/doi/10.1002/jia2.25422/full | https://doi.org/10.1002/jia2.25422
WHO strongly recommended implementing an indeterminate range to improve the accuracy of nucleic acid-based early infant diagnosis assays in 2018 [20]. In line with global guidelines, Mozambique has been implementing an indeterminate range, when interpreting early infant diagnosis test results. Even though detectable, all infants with an EID result equal to or above a cycle threshold of 31 on the Roche CAP/CTM HIV-1 qualitative v2 technology require additional testing, preferably on the same sample, prior to return of the result to the facility. Mozambique began implementing an indeterminate range prior to the 2018 WHO guidelines and thus had determined that an indeterminate range of 31 using the Roche CAP/CTM EID assay was preferable in their setting. Furthermore, it is important to note that the Ct values of an indeterminate range will vary across different assays. Interestingly, if we ignored the indeterminate range and definitive diagnosis, thus relying solely on whether the first EID test was detectable, the false-positive rate of the EID assay was 4.0%. There were four false-positive results using the initial EID test, all of which were negative using the viral load assay. Relying on the detectability and manufacturer result interpretation of a single EID test would have resulted in these infants being considered HIV-positive and potentially put on lifelong treatment unnecessarily. Although confirmatory testing is recommended globally and in nearly all countries, implementation has been poor and thus cannot be relied on entirely to prevent false-positive infants being put on treatment unnecessarily [6,21]. These data reiterate the importance of implementing an indeterminate range for test results with low levels of viraemia, particularly in countries with high antiretroviral drug exposure and decreasing mother to child transmission rates, in order to reduce the proportion of false positives and potential unnecessary lifelong treatment [20,21].

Significant challenges and barriers to increasing timely access to early infant diagnosis continue to stall the success of EID systems, including lack of price parity with viral load assays, reagent stockouts, duplicative workflows and sample batching. Utilizing viral load as an infant diagnostic test may support a more efficient laboratory system. Reagents would be purchased at the time of sample collection. Similar data were observed previously [22]. Using viral load as an infant diagnostic within current programmatic settings in high HIV burden countries. Policy adoption and early implementation can be considered to maximize resources, streamline laboratory systems and provide greater access to testing. When used to monitor patients on treatment, plasma is the preferred sample type for viral load testing [22]; however, dried blood spots are the preferred sample type for early infant diagnosis in Mozambique and many other high burden countries. This study did not review the performance of other sample types, including plasma, and it should be noted that the dried blood spot samples for viral load testing were processed similarly to those for EID (i.e. using SPEX buffer) before extraction and amplification using the viral load assay. Repeat testing was unfortunately not available for all indeterminate cases either on the same specimen or a new specimen (n = 4). This may have been due to one or several programmatic challenges and highlights the real world nature of this study. Although all were detectable initially, they had a Ct value greater than 31. These cases were reported as positive based on that first test and, though the viral load result was not incorporated within the diagnostic interpretation, all had a detectable viral load.

Interestingly, the age at testing was significantly different between the HIV-positive and HIV-negative infants. HIV-positive infants were nearly twice as old as the HIV-negative infants (64.5 vs. 33 days) at the time of sample collection. Similar data were reported as positive based on that first test and, though the viral load result was not incorporated within the diagnostic interpretation, all had a detectable viral load.

In order to support implementation of using viral load as an infant diagnostic, manufacturers would ideally seek regulatory approval within their current and/or future viral load assays’ intended use claims. In fact, dual claims have been sought by suppliers already [21]. Using viral load as an infant diagnostic would simplify supplier manufacturing since only viral load reagents would be needed and allow suppliers to focus on producing and supporting this primary, high volume product. Additionally, there are now point-of-care and near point-of-care early infant diagnosis as well as viral load assays that could be considered for dual claim regulatory approval processes and implementation.

There were several limitations in this study. This study was not powered to conduct sub-analyses based on treatment exposure or time at testing. Ideally similar studies for additional technologies would be conducted; however, the present study provides a clear proof of principle and confirmation that viral load can be used as an infant diagnostic within current programmatic settings in high HIV burden countries. Policy adoption and early implementation can be considered to maximize resources, streamline laboratory systems and provide greater access to testing. When used to monitor patients on treatment, plasma is the preferred sample type for viral load testing [22]; however, dried blood spots are the preferred sample type for early infant diagnosis in Mozambique and many other high burden countries. This study did not review the performance of other sample types, including plasma, and it should be noted that the dried blood spot samples for viral load testing were processed similarly to those for EID (i.e. using SPEX buffer) before extraction and amplification using the viral load assay. Repeat testing was unfortunately not available for all indeterminate cases either on the same specimen or a new specimen (n = 4). This may have been due to one or several programmatic challenges and highlights the real world nature of this study. Although all were detectable initially, they had a Ct value greater than 31. These cases were reported as positive based on that first test and, though the viral load result was not incorporated within the diagnostic interpretation, all had a detectable viral load.

Interestingly, the age at testing was significantly different between the HIV-positive and HIV-negative infants. HIV-positive infants were nearly twice as old as the HIV-negative infants (64.5 vs. 33 days) at the time of sample collection. Similar data were observed previously [23,24]. No test reconstitution forms were returned to the study team. The specimen was a later testing timepoint in the early infant diagnosis algorithm. Presumably, this may have been in part due to late mother-child presentation to the health care facility, perhaps due to stigma and discrimination issues, healthcare worker attitudes, or weak case-finding strategies, and may need further study. Furthermore, late presentation may also be correlated with other characteristics that hinder service utilization and/or retention of mothers and infants, such as young maternal age and status disclosure [25,26]. Additionally, though nearly 90% of mothers of HIV-positive infants were on treatment, the proportion was significantly lower than the mothers of HIV-negative infants (96.5%). The high rate of HIV-positive infants from women on ART was surprising and suggests the need for better adherence support, earlier identification and initiation of ART, and more effective ART regimens for HIV-positive pregnant women. No differences were observed between the groups with regards to infant prophylaxis, perhaps indicating that many of the HIV-positive infants were infected in utero before birth and initiation of infant prophylaxis. Expansion and improvements in prevention of mother to child transmission services and ensuring mothers are closely adherent to treatment throughout pregnancy and breastfeeding are critical.
5 | CONCLUSIONS

The results in this study highlight that viral load quantitative assays can be used as an infant diagnostic test. This may allow for streamlined manufacturing as well as simplified laboratory logistics and procurement, while also providing additional clinical information. However, it is imperative that manufacturers submit the appropriate change notification to regulatory bodies in order to fully supply countries considering implementation. As early infant diagnosis coverage rates have remained stagnant over recent years, tried and novel case-finding interventions coupled with the intervention presented here may be necessary to improve access to this essential test as it remains a gateway to identification of HIV-infected infants in need of life-saving treatment.

AUTHORS’ AFFILIATIONS

1 Instituto Nacional de Saúde, Maputo, Mozambique; 2Clinton Health Access Initiative, Maputo, Mozambique; 3Department of Mathematics and Informatics, Universidade Eduardo Mondlane, Maputo, Mozambique; 4World Health Organization, Geneva, Switzerland

COMPETING INTEREST

The authors declare no competing interest.

AUTHORS’ CONTRIBUTIONS

AV designed study, oversaw testing, collated data, interpreted results, substantially commented on the manuscript drafts and approved the finalized version of the manuscript. CN, BM, and NM conducted testing, collated data, interpreted results, substantially commented on the manuscript drafts and approved the finalized version of the manuscript. TB and JA interpreted results, substantially commented on the manuscript drafts and approved the finalized version of the manuscript. OL conducted data analysis, interpreted results, substantially commented on the manuscript drafts and approved the finalized version of the manuscript. UI and LV: designed study, interpreted results, wrote the first draft and produced the final version of the manuscript.

ACKNOWLEDGEMENTS

We would like to gratefully acknowledge the laboratory staff at Laboratório de Virologia Molecular at the Instituto Nacional de Saúde-Mozambique. This work was supported by Unitaid and WHO.

FUNDING

This study was supported by Unitaid and World Health Organization. [Correction added on 21 March 2020, after first online publication: The abbreviations have been updated throughout the article to improve clarity.]

REFERENCES

1. UNAIDS. Joint United Nations Programme on HIV/AIDS. Global AIDS Update Miles to go: closing gaps, breaking barriers, rights injustices. UNAIDS. 2018.
2. UNAIDS. Start free Stay Free AIDS Free: 2017 progress report. UNAIDS. 2017.
3. Boune DE, Thompson M, Brody LL, Cotton M, Draper B, Laubscher R et al. Emergence of a peak in early infant mortality due to HIV/AIDS in South Africa. AIDS. 2009;23:101–6.
4. Newell M, Coovadia H, Cortina-Borja M, Rollins N, Gaillard P, Dabis F, et al. Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis. Lancet. 2004;364:1236–43.
5. Ghadrireshas A, Amor YB, Chang J, Dale H, Sherman G, Vojnov L et al. Improved access to early infant diagnosis is a critical part of child-centric prevention of mother-to-child transmission agenda. AIDS. 2013;27 Suppl 2:S197–205.
6. World Health Organization. WHO recommendations on the diagnosis of HIV infection in infants and children. Geneva: World Health Organization, 2010.
7. Simonds RJ, Brown TM, Thea DM, Orlaff SL, Steketee RW, Lee FK et al. Sensitivity and specificity of a qualitative RNA detection assay to diagnose HIV infection in young infants. AIDS. 1998;12:1545–9.
8. Nesheim S, Palumbo P, Sullivan K, Lee F, Vink P, Abrams E et al. Quantitative RNA testing for diagnosis of HIV-infected infants. JAIDS. 2003;32:192–5.
9. Delamare C, Burgard M, Marjaux MJ, Blanche S, Ouaissi A, Ivanoft S, et al. HIV-1 RNA detection in plasma for the diagnosis of infection in neonates. J Acquir Immune Defic Syndr Hum Retrovirology. 1997;15(2):121–5.
10. Chaisa CS, Hugdens MG, Jamieson DJ, Kayira D, Hosseinipour MC, Kourtis AP, et al. Maternal or infant antiretroviral drugs to reduce HIV transmission. N Engl J Med. 2010;362:2271–81.
11. Kilewo C, Karlsson K, Ngarina M, Massawe A, Lyamuya E, Saiwi A et al. Prevention of Mother-to-Child transmission of HIV-1 through breastfeeding by treating mothers with triple antiretroviral therapy in Dar es Salaam, Tanzania: the Mitra Plus Study. J Acquir Immune Defic Syndr. 2009;52:406–16.
12. Shapiro RL, Hughes MD, Oguw A, Lockman S, Moffat C, Makheja J et al. Antiretroviral Regimens in pregnancy and breastfeeding in Botswana. N Engl J Med. 2010;362:2282–94.
13. The Kesho Bora Study Group. Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial. Lancet Infect Dis. 2011;11:171–80.
14. Thomas TK, Masaba R, Borkow CB, Ndlovu R, Zeh C, Misore A et al. Triple-antiretroviral prophylaxis to prevent mother-to-child HIV transmission through breastfeeding—the kisumu breastfeeding study, Kenya: a clinical trial. PLoS Medicine. 2011;8:e1001015.
15. Haeri Mazandarani A, Moyo F, Kufa T, Sherman G. Declining baseline viremia and escalating discordant HIV-1 confirmatory results within South Africa’s early infant diagnosis program, 2010–2016. J Acquir Immune Defic Syndr. 2016;77:212–216.
16. Alvarez P, Martin L, Prieto L, Obiang J, Vargas A, Avedillo P, et al. HIV-1 variability and viral load technique could lead to false positive HIV-1 detection and to erroneous viral quantification in infected specimens. J Infect. 2015;71(3):368–76.
17. Alvarez P, Prieto L, Martin L, Obiang J, Avedillo P, Vargas A, et al. Evaluation of four commercial virological assays for early infant HIV-1 diagnosis using dried blood specimens. Pediatr Res. 2017;81(1–2):80–7.
18. Kageha S, Okoth V, Kadima S, Vihenda S, Okapesi E, Nyambura E et al. Discrepant test findings in early infant diagnosis of HIV in a national reference laboratory in Kenya: challenges and opportunities for programs. J Trop Pediatr. 2012;58(4):247–52.
19. World Health Organization. Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV: interim guidelines. Supplement to the 2016 consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Geneva: World Health Organization. 2016.
20. World Health Organization. HIV diagnosis and ARV use in HIV-exposed infants: a programmatic update. Geneva: World Health Organization, 2018.
21. World Health Organization. WHO prequalification of in vitro diagnostics public report for aptima HIV-1 quant Dx assay. February 2018, version 5.0. [cited 2019 Mar 1]. Available from: https://www.who.int/diagnostics_laboratory/evaluations/pq-list/180207_fnal_pqpr_0236_078_00_v5_IFU-v4.pdf?ua=1
22. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. Geneva: World Health Organization, 2016.
23. Jani IV, Meggi B, Loquiha O, Tobaiwa O, Mudenyanga C, Zitha A et al. Effect of point-of-care early infant diagnosis on antiretroviral therapy initiation and retention of patients. AIDS. 2018;32:1453–63.
24. Mwenda R, Fong Y, Magombo T, Saka E, Muhandi D, Mwise C et al. Significant patient impact observed upon implementation of point-of-care early infant diagnosis technologies in an observational study in Malawi. Clin Infect Dis. 2018;67(5):701–7.
25. Dzangare J, Takarinda KC, Harries AD, Tayler-Smith K, Mhangara M, Apollo TM et al. HIV testing uptake and retention in care of HIV-infected pregnant and breastfeeding women initiated on Option B+ in rural Zimbabwe. Trop Med Int Health. 2016;21(2):202–9.
26. Kipoi Z, Dobkin LM, Mayaux MJ, Blanche S, Ouaissi A, Ivanoft S et al. Late-disease stage at presentation to an HIV clinic in the era of free antiretroviral therapy in sub-Saharan Africa. J Acquir Immune Defic Syndr. 2009;52(2):289–90.

SUPPORTING INFORMATION

Additional information may be found under the Supporting Information tab for this article.

Table S1. Cycle threshold values for the qualitative (EID) and quantitative (VL) tests of each HIV-positive infant